Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| astrocyte | 6 studies | 27% ± 9% | |
| oligodendrocyte precursor cell | 5 studies | 25% ± 9% | |
| epithelial cell | 4 studies | 34% ± 18% | |
| GABAergic neuron | 4 studies | 26% ± 8% | |
| glutamatergic neuron | 4 studies | 22% ± 4% | |
| abnormal cell | 3 studies | 18% ± 2% | |
| interneuron | 3 studies | 32% ± 12% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 4 studies | 22% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 1950.36 | 1444 / 1445 | 100% | 21.80 | 183 / 183 |
| intestine | 100% | 1684.17 | 966 / 966 | 100% | 16.62 | 526 / 527 |
| breast | 100% | 2632.55 | 459 / 459 | 100% | 18.44 | 1115 / 1118 |
| thymus | 100% | 1723.96 | 652 / 653 | 100% | 16.63 | 604 / 605 |
| stomach | 100% | 1914.87 | 359 / 359 | 100% | 17.24 | 285 / 286 |
| uterus | 100% | 3140.25 | 170 / 170 | 99% | 17.11 | 456 / 459 |
| lung | 99% | 1761.69 | 574 / 578 | 99% | 15.07 | 1149 / 1155 |
| pancreas | 99% | 1154.24 | 324 / 328 | 100% | 14.14 | 178 / 178 |
| ovary | 99% | 1208.36 | 179 / 180 | 99% | 11.18 | 425 / 430 |
| bladder | 100% | 1790.05 | 21 / 21 | 98% | 14.67 | 495 / 504 |
| skin | 100% | 3713.96 | 1809 / 1809 | 98% | 24.60 | 462 / 472 |
| prostate | 100% | 1847.37 | 245 / 245 | 98% | 12.03 | 490 / 502 |
| kidney | 100% | 1109.82 | 89 / 89 | 96% | 15.39 | 863 / 901 |
| brain | 86% | 731.51 | 2269 / 2642 | 100% | 14.64 | 704 / 705 |
| adrenal gland | 100% | 1924.03 | 257 / 258 | 84% | 6.38 | 194 / 230 |
| liver | 56% | 341.62 | 126 / 226 | 62% | 4.25 | 253 / 406 |
| adipose | 100% | 2456.34 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 33.03 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 8.97 | 29 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 21.93 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 5.85 | 1 / 1 |
| blood vessel | 100% | 1836.74 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 98% | 699.63 | 235 / 241 | 0% | 0 | 0 / 0 |
| muscle | 89% | 899.74 | 713 / 803 | 0% | 0 | 0 / 0 |
| heart | 87% | 726.96 | 753 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 59% | 776.29 | 548 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0023035 | Biological process | CD40 signaling pathway |
| GO_0042092 | Biological process | type 2 immune response |
| GO_0006954 | Biological process | inflammatory response |
| GO_1990959 | Biological process | eosinophil homeostasis |
| GO_0038173 | Biological process | interleukin-17A-mediated signaling pathway |
| GO_0072538 | Biological process | T-helper 17 type immune response |
| GO_0097400 | Biological process | interleukin-17-mediated signaling pathway |
| GO_0001783 | Biological process | B cell apoptotic process |
| GO_0007507 | Biological process | heart development |
| GO_0002269 | Biological process | leukocyte activation involved in inflammatory response |
| GO_0048535 | Biological process | lymph node development |
| GO_0002447 | Biological process | eosinophil mediated immunity |
| GO_0001822 | Biological process | kidney development |
| GO_0048255 | Biological process | mRNA stabilization |
| GO_0001782 | Biological process | B cell homeostasis |
| GO_0048536 | Biological process | spleen development |
| GO_0006959 | Biological process | humoral immune response |
| GO_0023019 | Biological process | signal transduction involved in regulation of gene expression |
| GO_0002344 | Biological process | B cell affinity maturation |
| GO_0030217 | Biological process | T cell differentiation |
| GO_0001768 | Biological process | establishment of T cell polarity |
| GO_0035556 | Biological process | intracellular signal transduction |
| GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
| GO_0006606 | Biological process | protein import into nucleus |
| GO_0110012 | Biological process | protein localization to P-body |
| GO_0070534 | Biological process | protein K63-linked ubiquitination |
| GO_0002334 | Biological process | transitional two stage B cell differentiation |
| GO_0009410 | Biological process | response to xenobiotic stimulus |
| GO_0070254 | Biological process | mucus secretion |
| GO_0043588 | Biological process | skin development |
| GO_0002230 | Biological process | positive regulation of defense response to virus by host |
| GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
| GO_0042119 | Biological process | neutrophil activation |
| GO_0005575 | Cellular component | cellular_component |
| GO_0031410 | Cellular component | cytoplasmic vesicle |
| GO_0031234 | Cellular component | extrinsic component of cytoplasmic side of plasma membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0061630 | Molecular function | ubiquitin protein ligase activity |
| GO_0005102 | Molecular function | signaling receptor binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | TRAF3IP2 |
| Protein name | TRAF3 interacting protein 2 E3 ubiquitin ligase TRAF3IP2 (EC 2.3.2.27) (Adapter protein CIKS) (Connection to IKK and SAPK/JNK) (E3 ubiquitin-protein ligase CIKS) (Nuclear factor NF-kappa-B activator 1) (ACT1) (TRAF3-interacting protein 2) |
| Synonyms | C6orf6 C6orf4 C6orf5 C6orf2 |
| Description | FUNCTION: E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling . Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein . Essential adapter molecule in IL17A-mediated signaling . Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways . . |
| Accessions | A0A8V8TQD6 ENST00000651547.2 [O43734-2] A0A494C1J9 ENST00000368730.5 [O43734-4] ENST00000368761.11 [O43734-2] A0A494C0G2 A0A494C0I3 ENST00000359831.8 [O43734-5] ENST00000340026.10 [O43734-1] ENST00000650649.1 ENST00000464903.1 A0A494C0R7 ENST00000699910.1 O43734 ENST00000651359.1 ENST00000368734.5 [O43734-4] ENST00000368735.1 [O43734-4] ENST00000492671.1 |
